Cevostamab in Combination With Pomalidomide and Dexamethasone after BCMA-Targeting CAR T-Cell Therapy in Patients With Previously Treated Multiple Myeloma

Prior treatment

• Any concurrent medical or psychiatric condition or disease that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study

Other illness

• History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant antibody-related fusion proteins) or known hypersensitivity to any of the excipients of cevostamab
• Gastrointestinal (GI) disease that might significantly alter absorption of oral drugs

Lab values

• Known history of amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan)
• Plasma cell leukemia or circulating plasma cell count exceeding 500 cells/µL or 5% of the peripheral blood white cells

Other

• Lesions in proximity of vital organs that may develop sudden decompensation/deterioration in the setting of a tumor flare

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment. - Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible
• Life expectancy of at least 12 weeks
• Received prior B-cell maturation antigen (BCMA)-targeting Chimeric Antigen Receptors (CAR) T-cell therapy –Only one prior line of CAR T-cell therapy in any prior treatment line is allowed
• Resolution of adverse events (including peripheral neuropathy) from prior anti‑cancer therapy to Grade ≤ 1, with the exception of any grade alopecia
• MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
• Is triple-class exposed, i.e. received anti-cluster of differentiation 38 (CD38) therapy, a proteasome inhibitor (PI) and lenalidomide in any prior line